BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Verastem, Inc. (VSTM) Buys Pfizer Inc. (PFE) Cancer Drug Candidate in Deal Worth $126.5 Million


7/11/2012 3:06:34 PM

Eisai and Versatem inked a research collaboration focused on the development of small molecule Wnt inhibitors. Verastem separately reported acquiring exclusive global rights to Pfizer’s Phase II-ready focal adhesion kinase (FAK) inhibitor PF-04554878. The drug, designated VS-6063 by Verastem, is being developed for the treatment of solid tumors and is projected to start in Phase II development for treating mesothelioma next year. The new partnership with Eisai will use Verastem’s salinomycin candidate VS-507 as the starting point for the development of new analogs that target cancer stem cells. Verastem has put further development of VS-507 itself on hold in order to push on with other priority candidates. Compounds identified through the Eisai collaboration will be tested using Verastem’s Wnt signalling and cancer stem cell assays. The firm will retain ownership of compounds developed during the 12-month collaboration, with Eisai receiving royalties on future commercial sales of products, and retaining rights of first negotiation for development.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->